Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


Study of BMS-986158 in Subjects With Select Advanced Cancers - CA011-001

Updated: 27 August, 2018   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participants Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2


  • Gender(s)

  • 12+

    Age Range

  • 10


  • Recruiting

Treatment Options

Study Arms
Experimental: Combination Therapy
Drug: BMS-986158 Biological: Nivolumab
Experimental: Monotherapy Treatment
Drug: BMS-986158

Key Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Males and females 12 years old or older - Must have select advanced cancers with specific genetic profiles - Must have received appropriate standard of care - At least one measurable lesion at baseline - Expected to have life expectancy of at least 3 months - Eastern Cooperative Oncology Group (ECOG) of 0 to 1 Exclusion Criteria: - Concomitant second malignancies - Uncontrolled or significant cardiovascular disease - Inadequate bone marrow function - Chronic gastrointestinal illness - Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor Other protocol defined inclusion/exclusion criteria could apply

Have questions? Call 855-907-3286 or Email Us

Have questions?
Call 855-907-3286 or Email Us